Home
/
RECURSION PHARMACEUTICALS, INC.
/
Financials
/
Quarterly
RECURSION PHARMACEUTICALS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that RECURSION PHARMACEUTICALS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$5.18M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$19.22M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$14.75M
May 5, 2025
Q3
2025
Sep 30, 2024
$26.08M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$14.42M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$13.79M
May 5, 2025
Q3
2024
Sep 30, 2023
$10.53M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$11.02M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$12.13M
May 9, 2024
Q3
2023
Sep 30, 2022
$13.16M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$7.67M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$5.33M
May 8, 2023
Q3
2022
Sep 30, 2021
$2.53M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$2.55M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$2.56M
May 10, 2022
Q3
2021
Sep 30, 2020
$1.03M
Nov 10, 2021
Q2
2021
Jun 30, 2020
$186.0K
Aug 13, 2021
Q1
2021
Mar 31, 2020
$60.0K
May 12, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($162.25M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($171.90M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($202.49M)
May 5, 2025
Q3
2025
Sep 30, 2024
($95.84M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($97.54M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($91.37M)
May 5, 2025
Q3
2024
Sep 30, 2023
($93.02M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($76.73M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($65.33M)
May 9, 2024
Q3
2023
Sep 30, 2022
($60.45M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($65.56M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($55.98M)
May 8, 2023
Q3
2022
Sep 30, 2021
($47.43M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($43.40M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($30.72M)
May 10, 2022
Q3
2021
Sep 30, 2020
($23.87M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($18.94M)
Aug 13, 2021
Q1
2021
Mar 31, 2020
($18.42M)
May 12, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($172.20M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($176.23M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($191.37M)
May 5, 2025
Q3
2025
Sep 30, 2024
($98.35M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($100.54M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($96.34M)
May 5, 2025
Q3
2024
Sep 30, 2023
($99.55M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($81.72M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($69.87M)
May 9, 2024
Q3
2023
Sep 30, 2022
($62.57M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($66.19M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($55.98M)
May 8, 2023
Q3
2022
Sep 30, 2021
($46.40M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($40.93M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($30.48M)
May 10, 2022
Q3
2021
Sep 30, 2020
($22.47M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($18.22M)
Aug 13, 2021
Q1
2021
Mar 31, 2020
($18.34M)
May 12, 2021